Here are five things to notes:
1. Through the alliance, the company aims to develop and commercialize novel therapies for specialty gastrointestinal diseases using enGene’s gene delivery platform, Gene Pill.
2. Under the terms of the agreement, enGene will develop up to two undisclosed targets selected by Takeda.
3. Takeda will have an option to exclusively license the global rights for the product candidates.
4. Following option exercise, Takeda will be responsible for all clinical development and commercialization of those products.
5. Takeda will also collaborate with enGene to develop the Gene Pill into a platform for oral delivery of antibodies.
More articles on GI/endoscopy:
6 GI physicians in the news – Jan. 8, 2016
Dr. Sandra Jara joins Gastroenterology Group of Naples
New modeling data suggests using Cologuard every 3 years
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.